{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:13:18Z","timestamp":1788459198380,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sci.","Brain Sciences"],"abstract":"<jats:p>Background\/Objectives: Schizophrenia causes substantial disability and reduced life expectancy, while symptoms frequently persist despite antipsychotic treatment. Long-chain n-3 polyunsaturated fatty acids (n-3 PUFAs) have been proposed as adjunctive therapy because of their anti-inflammatory and neurobiological properties. This systematic review and exploratory meta-analysis evaluated the efficacy and safety of adjunctive n-3 PUFAs in adults with schizophrenia. Methods: The review followed PRISMA 2020 and was prospectively registered in PROSPERO (CRD420251178174). PubMed, Web of Science, Scopus, Ovid, CENTRAL, ClinicalTrials.gov, and ICTRP were searched without language or date restrictions. Randomized controlled trials of n-3 PUFAs added to antipsychotic therapy were included. Risk of bias was assessed using RoB 2. PANSS scores were pooled as mean differences (MDs) using an inverse-variance random-effects model with REML estimation; dichotomous outcomes were pooled as risk ratios (RRs) using an inverse-variance random-effects model with the DerSimonian\u2013Laird estimator or a fixed-effect model with the Mantel\u2013Haenszel method, with a 0.5 continuity correction for zero cells. Results: Of 301 records, 10 randomized controlled trials met the eligibility criteria. Where sufficient comparable data were available, exploratory meta-analyses were conducted. Only one trial provided strict intention-to-treat final PANSS total data. A two-trial sensitivity meta-analysis (116 participants) showed no significant reduction in final PANSS total scores (MD \u22125.04, 95% CI \u221214.16 to 4.08; I2 = 55.8%). Results were also nonsignificant for clinical response (RR 1.62, 95% CI 0.27\u20139.78), all-cause discontinuation (RR 1.32, 95% CI 0.31\u20135.65), and discontinuation due to adverse events (RR 1.35, 95% CI 0.38\u20134.81). Extreme sensitivity analyses remained nonsignificant. Subgroup signals involving clozapine or baseline fatty-acid status were not consistently replicated. Evidence was limited by few studies, attrition, and substantial heterogeneity in n-3 PUFA formulation, dose, duration, population, and concomitant antipsychotic therapy. Conclusions: Current evidence does not support routine adjunctive n-3 PUFAs for symptom reduction in adults with schizophrenia. The available data cannot identify an optimal EPA\/DHA formulation, dose, or responsive clinical subgroup; larger biomarker-informed trials are needed.<\/jats:p>","DOI":"10.3390\/brainsci16090928","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:41:18Z","timestamp":1788266478000},"page":"928","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Omega-3 Polyunsaturated Fatty Acids as Adjunctive Therapy to Antipsychotic Treatment in Adults with Schizophrenia: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3910-3413","authenticated-orcid":false,"given":"Aura Patricia","family":"Yepes Sarmiento","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thayra","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Barrios","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-431X","authenticated-orcid":false,"given":"Hernan F.","family":"Guillen-Burgos","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"},{"name":"Center for Clinical and Translational Research, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla 080002, Colombia"},{"name":"Department of Psychiatry and Mental Health, Pontificia Universidad Javeriana, Bogot\u00e1 D.C. 110111, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Saha, S., Chant, D., Welham, J., and McGrath, J. (2005). A systematic review of the prevalence of schizophrenia. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020141"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/schbul\/sby095","article-title":"How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials","volume":"45","author":"Samara","year":"2019","journal-title":"Schizophr. Bull."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrn3820","article-title":"Polyunsaturated fatty acids and their metabolites in brain function and disease","volume":"15","author":"Bazinet","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/pr.117.014092","article-title":"Anti-Inflammatory Effects of Omega-3 Fatty Acids in the Brain: Physiological Mechanisms and Relevance to Pharmacology","volume":"70","author":"Nadjar","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_6","first-page":"103","article-title":"Desaturase and elongase-limiting endogenous long-chain polyunsaturated fatty acid biosynthesis","volume":"19","author":"Zhang","year":"2016","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chilton, F.H., Dutta, R., Reynolds, L.M., Sergeant, S., Mathias, R.A., and Seeds, M.C. (2017). Precision Nutrition and Omega-3 Polyunsaturated Fatty Acids: A Case for Personalized Supplementation Approaches for the Prevention and Management of Human Diseases. Nutrients, 9.","DOI":"10.3390\/nu9111165"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.scog.2017.05.001","article-title":"Omega-3 fatty acids related to cognitive impairment in patients with schizophrenia","volume":"9","author":"Satogami","year":"2017","journal-title":"Schizophr. Res. Cogn."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101347","DOI":"10.1016\/j.avb.2019.101347","article-title":"Omega-3 fatty acids in cause, prevention and management of violence in schizophrenia: Conceptualization and application","volume":"50","author":"Ouyang","year":"2020","journal-title":"Aggress. Violent Behav."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0920-9964(97)00151-5","article-title":"The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia","volume":"30","author":"Horrobin","year":"1998","journal-title":"Schizophr. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/0269881120981392","article-title":"Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials","volume":"35","author":"Goh","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1192\/j.eurpsy.2024.1804","article-title":"The therapeutic effect of omega-3 polyunsaturated fatty acids on symptom severity of psychosis: A systematic review and meta-analysis","volume":"67","author":"Rossier","year":"2024","journal-title":"Eur. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/schbul\/sbae186","article-title":"Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial","volume":"51","author":"Slot","year":"2025","journal-title":"Schizophr. Bull."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/tp.2013.110","article-title":"A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia","volume":"3","author":"Bentsen","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Qiao, Y., Liu, C.P., Han, H.Q., Liu, F.J., Shao, Y., and Xie, B. (2020). No impact of omega-3 fatty acid supplementation on symptoms or hostility among patients with schizophrenia. Front. Psychiatry, 11.","DOI":"10.3389\/fpsyt.2020.00312"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2017.08.026","article-title":"Effects of Omega-3 in the treatment of violent schizophrenia patients","volume":"195","author":"Qiao","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1179\/1476830514Y.0000000139","article-title":"Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol","volume":"19","author":"Vovk","year":"2016","journal-title":"Nutr. Neurosci."},{"key":"ref_20","first-page":"35","article-title":"Beneficial antipsychotic effects of omega-3 fatty acids add-on therapy for the pharmacological management of patients with schizophrenia","volume":"2","author":"Manteghiy","year":"2008","journal-title":"Iran. J. Psychiatry Behav. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2006.03.023","article-title":"The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial","volume":"84","author":"Emsley","year":"2006","journal-title":"Schizophr. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3956(01)00048-6","article-title":"A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms","volume":"36","author":"Peet","year":"2002","journal-title":"J. Psychiatr. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1176\/appi.ajp.159.9.1596","article-title":"Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia","volume":"159","author":"Emsley","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0920-9964(00)00083-9","article-title":"Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia","volume":"49","author":"Peet","year":"2001","journal-title":"Schizophr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1176\/appi.ajp.158.12.2071","article-title":"A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia","volume":"158","author":"Fenton","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102578","DOI":"10.1016\/j.plefa.2023.102578","article-title":"Association between PLA2 gene polymorphisms and treatment response to antipsychotic medications: A study of antipsychotic-na\u00efve first-episode psychosis patients and nonadherent chronic psychosis patients","volume":"194","author":"Nadalin","year":"2023","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102604","DOI":"10.1016\/j.plefa.2023.102604","article-title":"An association between PPAR\u03b1-L162V polymorphism and increased plasma LDL cholesterol levels after risperidone treatment","volume":"200","author":"Nadalin","year":"2024","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102665","DOI":"10.1016\/j.plefa.2025.102665","article-title":"Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients","volume":"204","author":"Nadalin","year":"2025","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JCP.0b013e318248b7bb","article-title":"Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies","volume":"32","author":"Berger","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials","volume":"53","author":"Cho","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bozzatello, P., Rocca, P., Mantelli, E., and Bellino, S. (2019). Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215257"},{"key":"ref_33","first-page":"CD001257","article-title":"Polyunsaturated fatty acid supplementation for schizophrenia","volume":"3","author":"Irving","year":"2006","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/9\/928\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:20:36Z","timestamp":1788456036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/9\/928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["brainsci16090928"],"URL":"https:\/\/doi.org\/10.3390\/brainsci16090928","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}